Neuropsychiatric adverse events associated with statins: Epidemiology, pathophysiology, prevention and management

CNS Drugs

Volumn 28, Issue 3, 2014, Pages 249-272

  Tuccori, Marco ^a,b   Montagnani, Sabrina ^c   Mantarro, Stefania ^c   Capogrosso Sansone, Alice ^c   Ruggiero, Elisa ^a,b   Saporiti, Alessandra ^c   Antonioli, Luca ^c   Fornai, Matteo ^c   Blandizzi, Corrado ^b,c  

^a Tuscan Regional Centre of Pharmacovigilance   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATORVASTATIN; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; OMEGA 3 FATTY ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; PSYCHOTROPIC AGENT; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

AGGRESSION; ALIENATION; ANTISOCIAL BEHAVIOR; ANXIETY; AROUSAL; BEHAVIOR DISORDER; CHOLESTEROL SYNTHESIS; COGNITIVE DEFECT; DEPRESSION; DIET RESTRICTION; ERECTILE DYSFUNCTION; HOSTILITY; HUMAN; IMPOTENCE; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; NIGHTMARE; NONHUMAN; PARANOIA; PATHOPHYSIOLOGY; PATIENT MONITORING; PENIS NOCTURNAL TUMESCENCE; POSTOPERATIVE DELIRIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SLEEP WALKING; SOMATIZATION; SOMNOLENCE; SUICIDE; VIOLENCE; ANIMAL; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; MENTAL DISORDERS;

ANIMALS; BRAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MENTAL DISORDERS;

EID: 84896824167     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0135-1     Document Type: Review

References (177)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-6.
2. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7:102-8.
3. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother. 2004;38:91-8.
4. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-7. doi: 10.1136/jnnp.2008.150433.
5. Kurata T, Kawai H, Miyazaki K, Kozuki M, Morimoto N, Ohta Y, Ikeda Y, Abe K. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. J Neurol Sci. 2012;322:59-63.
6. Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21:95-102.
7. Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, Berk M. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom. 2010;79:323-5.
8. Tapia-Perez J, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008;25:1011-7.
9. Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, Silva AJ, de Zeeuw CI, Moll HA, Elgersma Y. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA. 2008;300:287-94.
10. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30:195-201.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
12. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30.
13. Rutishauser J. Statins in clinical medicine. Swiss Med Wkly. 2011;21(141):w13310. doi: 10.4414/smw.2011.13310.
14. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet. 1993;341:114.
15. Lechleitner M, Hoppichler F, Konwalinka G, Patsch J, Braunsteiner H. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet. 1992;340:910.
16. Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, Motola D, Salvo F, Rivolta AL, Blandizzi C, Mugelli A, Del Tacca M. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2008;31:1115-23.
17. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231-6.
18. Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ. 1996;313:75-8.
19. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, Gordon DJ. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45:8-14.
20. Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-46.
21. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med. 2000;160:3144-52.
22. Hyyppä MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology. 2003;28:181-94.
23. Morales K, Wittink M, Datto C, DiFilippo S, Cary M, TenHave T, Katz IR. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc. 2006;54:70-6.
24. Ormiston T, Wolkowitz OM, Reus VI, Manfredi F. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics. 2003;44:412-4.
25. Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003;42:690-7.
26. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003;163:1926-32.
27. Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55:420-5.
28. Callréus T, Agerskov Andersen U, Hallas J, Andersen M. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol. 2007;63:591-6.
29. Luijendijk HJ, Stricker BH, Hofman A, Witteman JC, Tiemeier H. Cerebrovascular risk factors and incident depression in community-dwelling elderly. Acta Psychiatr Scand. 2008;118:139-48.
30. Lindberg G, Hallas J. Cholesterol-lowering drugs and antidepressants - a study of prescription symmetry. Pharmacoepidemiol Drug Saf. 1998;7:399-402.
31. Olson MB, Kelsey SF, Matthews KA, Bairey Merz CN, Eteiba W, McGorray SP, Cornell CE, Vido DA, Muldoon MF. Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. J Womens Health (Larchmt). 2008;17:187-94.
32. Feng L, Yap KB, Kua EH, Ng TP. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf. 2010;19:942-8.
33. Otte C, Zhao S, Whooley MA. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry. 2012;73:610-5.
34. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
35. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H, Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004;5:81-7.
36. Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ. 2008;179:645-52.
37. Katznelson R, Djaiani GN, Borger MA, Friedman Z, Abbey SE, Fedorko L, Karski J, Mitsakakis N, Carroll J, Beattie WS. Preoperative use of statins is associated with reduced early delirium rates after cardiac surgery. Anesthesiology. 2009;110:67-73.
38. Katznelson R, Djaiani G, Mitsakakis N, Lindsay TF, Tait G, Friedman Z, Wasowicz M, Beattie WS. Delirium following vascular surgery: increased incidence with preoperative beta-blocker administration. Can J Anaesth. 2009;56:793-801.
39. Mariscalco G, Cottini M, Zanobini M, Salis S, Dominici C, Banach M, Onorati F, Piffaretti G, Covaia G, Realini M, Beghi C. Preoperative statin therapy is not associated with a decrease in the incidence of delirium after cardiac operations. Ann Thorac Surg. 2012;93:1439-47.
40. Marcantonio ER. Statins and postoperative delirium. CMAJ. 2008;179:627-8.
41. Trottier M. Statins and memory loss. Canadian Adverse Reaction Newsletter. 2005;15(4). Health Canada. Available from http://www.hc-sc.gc.ca/ dhp-mps/medeff/bulletin/index-e.html.
42. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800-11.
43. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30:669-75.
44. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-96.
45. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39:333-6.
46. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209-14.
47. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72:805-12.
48. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25:1250-1.
49. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67.
50. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823-9.
51. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62:259-65.
52. Golomb BA, Dimsdale JE, White HL, Criqui MH. Do low dose statins affect cognition? Results of the UCSD Statin Study. Circulation. 2006;114:II-289.
53. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27:183-90.
54. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-31.
55. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50:1852-6.
56. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57:M414-8.
57. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-7.
58. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-84.
59. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, G van Belle, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63:1624-8.
60. Starr JM, McGurn B, Whiteman M, Pattie A, Whalley LJ, Deary IJ. Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry. 2004;19:327-32.
61. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC, Cache County Study Investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-24.
62. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71:344-50.
63. Horsdal HT, Olesen AV, Gasse C, Sørensen HT, Green RC, Johnsen SP. Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Assoc Disord. 2009;23:18-22.
64. Glasser SP, Wadley V, Judd S, Kana B, Prince V, Jenny N, Kissela B, Safford M, Prineas R, Howard G. The association of statin use and statin type and cognitive performance: analysis of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Clin Cardiol. 2010;33:280-8.
65. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, Zonderman AB. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011;65:949-57.
66. Ancelin ML, Carrière I, Barberger-Gateau P, Auriacombe S, Rouaud O, Fourlanos S, Berr C, Dupuy AM, Ritchie K. Lipid lowering agents, cognitive decline, and dementia: the Three-City Study. J Alzheimers Dis. 2012;30:629-37.
67. El Schaefer. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:1222-3.
68. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors. JAMA. 1990;264:1105.
69. Barth JD, Kruisbrink OA, Van Dijk AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. BMJ. 1990;301:669.
70. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther. 1991;50:730-7.
71. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426-32.
72. Eckernäs SA, Roos BE, Kvidal P, Eriksson LO, Block GA, Neafus RP, Haigh JR. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284-9.
73. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993;71:1408-14.
74. The Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol. 1993;71:810-5.
75. Partinen M, Pihl S, Strandberg T, Vanhanen H, Murtomäki E, Block G, Neafus R, Haigh J, Miettinen T, Reines S. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol. 1994;73:876-80.
76. Keech AC, Armitage JM, Wallendszus KR, Lawson A, Hauer AJ, Parish SE, Collins R. Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group. Br J Clin Pharmacol. 1996;42:483-90.
77. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, Higgins J, Langendorfer A, Nash DT, Pool JL, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-73.
78. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Arlington: American Psychiatric Association; 2013. dsm.psychiatryonline.org (Accessed 1 June 2013).
79. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother. 1996;30:192.
80. De Graaf L, Brouwers AHPM, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? Br J Clin Pharmacol. 2004;58:326-8.
81. Boyd IW. Comment: HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother. 1996;30:1199.
82. Carvajal A, Macias D, Sáinz M, Ortega S, Martín Arias LH, Velasco A, Bagheri H, Lapeyre-Mestre M, Montastruc JL. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29:143-9.
83. Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf. 2009;32:591-7.
84. Jackson G. Drug points: simvastatin and impotence. BMJ. 1997;315:31-2.
85. Pedersen TR, Faergeman O. Simvastatin seems unlikely to cause impotence. BMJ. 1999;318:192.
86. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89-94.
87. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, Peled H, Pollick C, Choudhary R, Rosen R, Padma-Nathan H. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46-50.
88. Solomon H, Samarasinghe YP, Feher MD, Man J, Rivas-Toro H, Lumb PJ, Wierzbicki AS, Jackson G. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract. 2006;60:141-5.
89. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol. 2004;172:255-8.
90. Corona G, Boddi V, Balercia G, Rastrelli G, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med. 2010;7:1547-56.
91. Mastalir ET, Carvalhal GF, Portal VL. The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin Treatment for Erectile Dysfunction - STED trial). Int J Impot Res. 2011;23:242-8.
92. Al-Ismaili Z, Piccioni M, Zappitelli M. Rhabdomyolysis: pathogenesis of renal injury and management. Pediatr Nephrol. 2011;26:1781-8.
93. Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med. 2004;164:153-62.
94. Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5:746-55.
95. Lütjohann D. Brain cholesterol and suicidal behaviour. Int J Neuropsychopharmacol. 2007;10:153-7.
96. Glueck CJ, Tieger M, Kunkel R, Hamer T, Tracy T, Speirs J. Hypocholesterolemia and affective disorders. Am J Med Sci. 1994;308:218-25.
97. Horsten M, Wamala SP, Vingerhoets A, Orth-Gomer K. Depressive symptoms, social support, and lipid profile in healthy middle-aged women. Psychosom Med. 1997;59:521-8.
98. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in older men. Lancet. 1993;341:75-9.
99. Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339:727-9.
100. Gallerani M, Manfredini R, Caracciolo S, Scapoli C, Molinari S, Fersini C. Serum cholesterol concentrations in parasuicide. BMJ. 1995;310:1632-6.
101. Golier JA, Marzuk PM, Leon AC, Weiner C, Tardiff K. Low serum cholesterol level and attempted suicide. Am J Psychiatry. 1995;152:419-23.
102. Kunugi H, Takei N, Aoki H, Nanko S. Low serum cholesterol in suicide attempters. Biol Psychiatry. 1997;41:196-200.
103. Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand. 1997;95:212-21.
104. Papassotiropoulos A, Hawellek B, Frahnert C, Rao GS, Rao ML. The risk of acute suicidality in psychiatric inpatients increases with low plasma cholesterol. Pharmacopsychiatry. 1999;32:1-4.
105. New AS, Sevin EM, Mitropoulou V, Reynolds D, Novotny SL, Callahan A, Trestman RL, Siever LJ. Serum cholesterol and impulsivity in personality disorders. Psychiatry Res. 1999;85:145-50.
106. Brown DW, Ketter TA, Crumlish J, Post RM. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol. 1992;12:431-7.
107. Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, Kotler M, Weizman A. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol. 1999;22:98-101.
108. Yeragani VK, Balon R, Pohl R, Ramesh C. Imipramine treatment and increased serum cholesterol levels. Can J Psychiatry. 1989;34:845.
109. Ghodke RM, Tour N, Devi K. Effects of statins and cholesterol on memory functions in mice. Metab Brain Dis. 2012;27:443-51.
110. Evans BA, Evans JE, Baker SP, Kane K, Swearer J, Hinerfeld D, Caselli R, Rogaeva E, St George-Hyslop P, Moonis M, Pollen DA. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27:519-24.
111. Tolias KF, Duman JG, Um K. Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog Neurobiol. 2011;94:133-48.
112. Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci. 2003;17:93-102.
113. Reiss AB, Wirkowski E. Statins in neurological disorders: mechanisms and therapeutic value. Sci World J. 2009;9:1242-59.
114. Tanaka T, Tatsuno I, Uchida D, Moroo I, Morio H, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Saito Y, Hirai A. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci. 2000;20:2852-9.
115. García-Román N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci. 2001;17:329-41.
116. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18:101-11.
117. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23:1663-7.
118. Hering H, Lin CC, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 2003;23:3262-71.
119. Kumar B, Andreatta C, Koustas WT, Cole WC, Edwards-Prasad J, Prasad KN. Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J Neurosci Res. 2002;68:627-35.
120. Cerezo-Guisado MI, Garcia-Roman N, Garcia-Marin LJ, Alvarez-Barrientos A, Bragado MJ, Lorenzo MJ. Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J. 2007;401:175-83.
121. Kannan M, Steinert JR, Forsythe ID, Smith AG, Chernova T. Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a hemeindependent manner. Neurobiol Aging. 2010;31:1543-53.
122. You H, Lu W, Zhao S, Hu Z, Zhang J. The relationship between statins and depression: a review of the literature. Expert Opin Pharmacother. 2013;14:1467-76.
123. Linetti A, Fratangeli A, Taverna E, Valnegri P, Francolini M, Cappello V, Matteoli M, Passafaro M, Rosa P. Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci. 2010;123:595-605.
124. Mateos MV, Salvador GA, Giusto NM. Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings. Biochim Biophys Acta. 2010;1798:624-36.
125. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry. 1995;28:45-50.
126. Fawcett J, Busch KA, Jacobs D, Kravitz HM, Fogg L. Suicide: a four-pathway clinical-biochemical model. Ann N Y Acad Sci. 1997;836:288-301.
127. Hawthon K, Cowen P, Owens D, Bond A, Elliott M. Low serum cholesterol and suicide. Br J Psychiatry. 1993;162:818-25.
128. Papaphilis A, Deliconstantinos G. Modulation of serotonergic receptors by exogenous cholesterol in the dog synaptosomal plasma membrane. Biochem Pharmacol. 1980;29:3325-7.
129. Maguire PA, Druse MJ. The influence of cholesterol on synaptic fluidity, dopamine D1 binding and dopamine-stimulated adenylate cyclase. Brain Res Bull. 1989;23:69-74.
130. Shih JC, Ohsawa R. Differential effect of cholesterol on two types of 5-hydroxytryptamine binding sites. Neurochem Res. 1983;8:701-10.
131. Heron DS, Shinitzky M, Hershkowitz M, Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Natl Acad Sci USA. 1980;77:7463-7.
132. Kaplan JR, Shively CA, Fontenot MB, Morgan TM, Howell SM, Manuck SB, Muldoon MF, Mann JJ. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom Med. 1994;56:479-84.
133. Kaplan JR, Muldoon MF, Manuck SB, Mann JJ. Assessing the observed relationship between low cholesterol and violence-related mortality. Implications for suicide risk. Ann N Y Acad Sci. 1997;836:57-80.
134. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-14.
135. Steegmans PH, Fekkes D, Hoes AW, Bak AA, van der Does E, Grobbee DE. Low serum cholesterol concentration and serotonin metabolism in men. BMJ. 1996;312:221.
136. Shrivastava S, Pucadyil TJ, Paila YD, Ganguly S, Chattopadhyay A. Chronic cholesterol depletion using statin impairs the function and dynamics of human serotonin(1A) receptors. Biochemistry. 2010;49:5426-35.
137. Nothdurfter C, Tanasic S, Di Benedetto B, Rammes G, Wagner EM, Kirmeier T, Ganal V, Kessler JS, Rein T, Holsboer F, Rupprecht R. Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology. 2010;35:1510-9.
138. Sjögren B, Hamblin MW, Svenningsson P. Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. Eur J Pharmacol. 2006;552:1-10.
139. Sjögren B, Csöregh L, Svenningsson P. Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:441-6.
140. Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Stárková L, Ceska R, Papezová H. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005;133:197-203.
141. Wang Q, Tang XN, Wang L, Yenari MA, Ying W, Goh BC, Lee HS, Wilder-Smith EP, Wong PT. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett. 2006;408:189-93.
142. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol. 1992;38:379-95.
143. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109-22.
144. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem. 2001;76:391-400.
145. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem. 1999;72:2278-85.
146. Risé P, Pazzucconi F, Sirtori CR, Galli C. Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis. 2001;11:88-94.
147. Levine L. Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids Health Dis. 2003;2:1.
148. de Lorgeril M, Salen P, Defaye P, Rabaeus M. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. 2013;11:5.
149. Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, Vaughan MR, Rawlings R, Salem N Jr. A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biol Psychiatry. 1998;44:243-9.
150. Conklin SM, Harris JI, Manuck SB, Yao JK, Hibbeln JR, Muldoon MF. Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. Psychiatry Res. 2007;152:1-10.
151. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr. 1995;62:1-9.
152. Crenshaw TL, Goldberg PJ. Testosterone in men. In: Crenshaw TL, Goldberg PJ, editors. Sexual pharmacology. New York: WW Norton Co.; 1996. p. 115-28.
153. Griffin JE, Wilson JD. Disorders of the testes. In: Braunwald E, Fauci AS, Kapser DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p. 2143-54.
154. Jay RH, Sturley RH, Stirling C, McGarrigle HH, Katz M, Reckless JP, Betteridge DJ. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol. 1991;32:417-22.
155. Ginsberg HN, Golberg IJ. Disorders of intermediary metabolism. In: Braunwald E, Fauci AS, Kapser DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p. 245-57.
156. Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res. 1996;28:193-8.
157. Smals AG, Weusten JJ, Benraad TJ, Kloppenborg PW. The HMGCoA reductase-inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid- oxidoreductase enzyme activity. J Steroid Biochem Mol Biol. 1991;38:465-8.
158. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190-2.
159. Wood RL, Cummins DF. Simvastatin- and fluvastatin-associated nightmares. J Pharm Pract. 2009;22:421-5.
160. Ali S, Khan SA, Iram S. Hypocholesterolemia secondary to atrovastatin therapy. J Ayub Med Coll Abbottabad. 2010;22:225-7.
161. Okeahialam BN, Isiguzoro I. Statin related memory dysfunction in a Nigerian woman: a case report. Curr Drug Saf. 2012;7:33-4.
162. Duits N, Bos FM. Psychiatric disorders with use of simvastatin. Ned Tijdschr Geneeskd. 1993;26(137):1312-5.
163. Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disturbances. Am J Med. 1993;95:548-9.
164. Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA. Sleep disturbance and appetite loss after lovastatin. Lancet. 1994;343:973.
165. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996;36:728-31.
166. Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother. 2001;35:1292.
167. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-9.
168. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-80.
169. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97:229-35.
170. Gregoor PJ. Atorvastatin may cause nightmares. BMJ. 2006;332:950.
171. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40:1880-3.
172. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. Am J Geriatr Pharmacother. 2008;6:28-32.
173. Healy D, Morgan R, Chinnaswamy S. Transient global amnesia associated with statin intake. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.06.2008.003.
174. Tobe E. Pseudodementia caused by severe depression. BMJ Case Rep. 2012;2012. doi: 10.1136/bcr-2012-007156.
175. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46:163-9.
176. Trifirò G, Alacqua M, Corrao S, Tari M, Arcoraci V. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials. J Am Geriatr Soc. 2008;56(1):175-7. doi: 10.1111/j.1532-5415.2007.01486.x.
177. Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry. 2002;35:1-5.